Semaglutide-Associated Acute Interstitial Nephritis: A Case Report

Borkum, Megan; Lau, Wynnie; Blanco, Paula; Farah, Myriam

doi:10.1016/j.xkme.2022.100561

Cited by 7 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been associated with severe gastrointestinal adverse events, gallbladder-related disorders, and hepatobiliary disorders ( 3 , 7 ). There have been also some reports of rare adverse events including hyperglycemia, acute pancreatitis, and acute nephritis ( 5 , 8 , 9 ). In the global phase 3 Semaglutide Treatment Effect in People with Obesity (STEP) program, no difference was found between semaglutide and placebo regarding psychiatric adverse effects ( 3 ).…”

Section: Introductionmentioning

confidence: 99%

Case Report: Semaglutide-associated depression: a report of two cases

Li,

Cao,

Wei

et al. 2023

Front. Psychiatry

View full text Add to dashboard Cite

Semaglutide, as a glucagon-like peptide-1 receptor agonist (GLP-1 RA), was approved for glucose control in type 2 diabetes mellitus in 2017 and approved for weight loss in 2021 by the U.S. Food and Drug Administration (FDA). No psychiatric adverse effect associated with semaglutide has been reported so far. Here we report two cases of semaglutide-associated depression. One is a middle-aged man with no previous history of depression who developed depressive symptoms about 1 month after taking semaglutide. The other one is a middle-aged woman with recurrent depressive disorder whose symptoms also recurred about 1 month after semaglutide treatment. Depression was improved or relieved after discontinuation of semaglutide in both cases. Possible psychiatric adverse effects of depression should be taken into consideration when semaglutide is administered to patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Case Report: Semaglutide-associated depression: a report of two cases

Li,

Cao,

Wei

et al. 2023

Front. Psychiatry

View full text Add to dashboard Cite

show abstract

Eosinophil-related diseases during treatment with glucagon-like peptide one receptor (GLP-1 RA): a case report and review of the literature

et al. 2023

View full text Add to dashboard Cite

Glucagon-like peptide one-receptor agonists (GLP-1 RA) are drugs that differ in their pharmacological composition and homology to human GLP-1 and are used most frequently for the treatment of type 2 diabetes and weight loss. There are isolated reports of eosinophilic adverse reactions associated with GLP-1 RA. We present the case of a 42-year-old female patient who, after starting weekly subcutaneous semaglutide, developed eosinophilic fasciitis with favorable clinical evolution after the discontinuation of semaglutide and the initiation of immunosuppression. A review of the eosinophilic adverse events that have been previously reported with GLP-1 RA is provided.

show abstract

Semaglutide

2023

Reactions Weekly

View full text Add to dashboard Cite

Semaglutide-Associated Acute Interstitial Nephritis: A Case Report

Cited by 7 publications

References 9 publications

Case Report: Semaglutide-associated depression: a report of two cases

Case Report: Semaglutide-associated depression: a report of two cases

Eosinophil-related diseases during treatment with glucagon-like peptide one receptor (GLP-1 RA): a case report and review of the literature

Semaglutide

Contact Info

Product

Resources

About